Brown-Séquard testicular extract (organotherapy)

The professor who used himself as the experiment

On 1 June 1889, a 72-year-old man stood before the Société de Biologie in Paris and reported that he had injected himself five times over eighteen days with a water extract of dog and guinea-pig testes, and that his physical and mental vigor had come back. The man was Charles-Édouard Brown-Séquard (8 April 1817 to 1 April 1894), and he was not a fringe figure. Mauritius-born and Paris-educated, he had held senior academic posts in Paris, London, Dublin, and at Harvard; the spinal-cord injury pattern still called Brown-Séquard syndrome is named for him; and since 1878 he had occupied the chair of experimental medicine at the Collège de France. It was that standing, plus the fact that the subject of the experiment was the experimenter himself, that lifted the announcement above the lay rejuvenation claims of his era and gave it immediate traction inside the profession.

From his own circle to every pharmacy in a year

The initial protocol was administered by Brown-Séquard to himself and to a small number of older men in his immediate circle. Within months of the June 1889 announcement, the protocol was being produced and distributed by Brown-Séquard and his assistant Jacques-Arsène d’Arsonval to physicians and colleagues across Europe. Within roughly a year it had been picked up by pharmacists and pharmaceutical manufacturers and was being sold as ‘Brown-Séquard’s elixir’ and similar testicular-extract preparations across Europe and North America. The patient population for the commercial product was the urban professional and upper-class male; the protocol moved from exclusive personal use to mass-elite distribution within a single year.

Right about the gland, wrong about the bottle

Brown-Séquard claimed that aqueous extract from the freshly removed testes of guinea pigs and dogs, when injected subcutaneously into an older male, would restore physical vigor, mental acuity, and various functional capacities. The proposed mechanism rested on the assumption that the testes secrete a ‘vital substance’ that diminishes with age and that exogenous supplementation can restore the lost function. The mechanistic premise prefigured modern endocrinology in concept (testes do secrete an active substance, later identified as testosterone) but failed in execution: the aqueous extract Brown-Séquard prepared contained essentially no testosterone. Modern reconstruction (Cussons et al, Med J Aust 2002) estimates the testosterone delivered per injection at roughly four orders of magnitude below any therapeutic dose.

He gave it away; others sold his name

Brown-Séquard and d’Arsonval initially distributed the extract free of charge to physicians as research material. Commercial production, marketing, and sale of ‘Brown-Séquard’s elixir’ was conducted by independent pharmacists and pharmaceutical manufacturers across Europe and North America from 1890 onward. Brown-Séquard himself did not directly profit from the commercial sale of the preparation. The conflict in this case is academic-reputational rather than direct-financial: the published announcement and subsequent claims preserved his professional standing in a domain his contemporaries had begun to consider eccentric. The pharmaceutical industry that grew up around the announcement, however, was a major commercial enterprise driven by Brown-Séquard’s published authority.

Dead in five years, the dose later measured at nothing

Brown-Séquard died on 1 April 1894 in Paris, less than five years after his announcement and without having demonstrated objective rejuvenation. Critical assessment within the scientific community began almost immediately; by the early twentieth century the broader project of ‘organotherapy’ had been narrowed to a few effective interventions (notably thyroid extract for myxedema, where the active substance is in fact present in the preparation) and most of the testicular and adrenal extracts were recognised as therapeutically inert. The canonical modern reassessment is Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP, ‘Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment,’ Medical Journal of Australia 2002;177(11-12):678-679, which reconstructed the testosterone dose and concluded that the reported clinical effects were necessarily attributable to placebo response.

Notes

On 1 June 1889 Charles-Édouard Brown-Séquard, then aged 72 and holding the chair of experimental medicine at the Collège de France, presented a communication to the Société de Biologie in Paris reporting that he had self-injected an aqueous extract of guinea-pig and dog testes and observed restoration of physical and mental vigor. The communication (“Effets produits chez l’homme par des injections sous-cutanées d’un liquide retiré des testicules frais de cobaye et de chien,” Comptes rendus de la Société de Biologie, 1 June 1889) was republished in expanded form in The Lancet (1889;2:105-107). Within a year the protocol was being commercialized across Europe and North America as “Brown-Séquard’s elixir” and related testicular-extract preparations. Brown-Séquard died in Paris on 1 April 1894, less than five years after his announcement. Modern reconstruction of the dosing (Cussons et al, Med J Aust 2002) shows the testosterone content of the extract was roughly 10,000-fold below any therapeutic level, and the reported clinical effects were necessarily a placebo response. The 1889 announcement is the founding event of modern elite-targeted rejuvenation medicine and the direct intellectual ancestor of subsequent biological-substance-transfer protocols including Voronoff’s testicular xenograft (1920), Niehans’s cellular therapy (1931), and contemporary TPE-IVIG (2024-present).

By David Wootton’s placebo bar (Bad Medicine, Oxford University Press, 2006, p. 68), the testicular-extract intervention is bad medicine. The Cussons et al 2002 dosing reconstruction places the active testosterone delivered at approximately 10,000-fold below any plausible therapeutic threshold, which means the entire reported clinical response can only be attributable to placebo. Against Wootton’s six obstacles to disconfirmation (pp. 144 to 149), the case satisfies each: illusion of success (Brown-Séquard’s self-reported vigor was within the normal short-term variation of a 72-year-old physiologist), placebo effect (the entire reported effect), patient-not-disease thinking (self-administered, then individually administered by physician-colleagues, no aggregated outcome), pressure to conform (the Société de Biologie’s institutional setting), absence of statistical thinking (no controlled comparison and no aggregation of cases), and tacit obligation to administer the available preparation to interested colleagues. Brown-Séquard sits structurally between the Perkins Tractors (1796 to 1810) and Voronoff (1920 to 1935) at the inflection point Wootton identifies between Hippocratic medicine and the late-19th-century commercial preservation of placebo-driven clinical ritual.